Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study (Q36155677)

12 August 2017

Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study (English)

1 reference

12 August 2017

Luca Bello

1

0 references

Craig M. McDonald

object named as

Craig M McDonald

8

0 references

Avital Cnaan

7

object named as

Avital Cnaan

1 reference

12 August 2017

Heather Gordish-Dressman

2

object named as

Heather Gordish-Dressman

1 reference

12 August 2017

6

Eric P Hoffman

1 reference

12 August 2017

Lauren P Morgenroth

3

1 reference

12 August 2017

Erik K Henricson

4

1 reference

12 August 2017

Tina Duong

5

1 reference

12 August 2017

CINRG Investigators

9

1 reference

12 August 2017

language of work or name

English

0 references

publication date

26 August 2015

1 reference

12 August 2017

1 reference

12 August 2017

85

1 reference

12 August 2017

12

1 reference

12 August 2017

1048-1055

1 reference

Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Steroids in Duchenne dystrophy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing an

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Corticosteroids in Duchenne muscular dystrophy: major variations in practice

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Glucocorticoid corticosteroids for Duchenne muscular dystrophy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Prednisolone-induced changes in dystrophic skeletal muscle

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Methylprednisolone increases dystrophin levels by inhibiting myotube death during myogenesis of normal human muscle in vitro

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Deflazacort treatment of Duchenne muscular dystrophy

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4603595

Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy

21 October 2018

1 reference

12 December 2020

1 reference

12 December 2020

Steroids in Duchenne muscular dystrophy

1 reference

12 December 2020

A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy

1 reference

12 December 2020

Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy

1 reference

12 December 2020

Prednisone in Duchenne muscular dystrophy

1 reference

12 December 2020

Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone

1 reference

12 December 2020

Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit

1 reference

12 December 2020

Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group

1 reference

12 December 2020

Long-term benefit from prednisone therapy in Duchenne muscular dystrophy

1 reference

12 December 2020

Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)

1 reference

12 December 2020

Deflazacort in Duchenne dystrophy: study of long-term effect

1 reference

12 December 2020

Prednisone can protect against exercise-induced muscle damage

1 reference

12 December 2020

10.1212/WNL.0000000000001950

Identifiers

DOI

1 reference

release_vvzvuzrfxrejjaunhkq4t7yv4q

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vvzvuzrfxrejjaunhkq4t7yv4q

24 November 2022

mapped directly with Wikidata item

1 reference

12 August 2017

PubMed publication ID

26311750

1 reference